Cargando…

Tenofovir Pre-exposure Prophylaxis for Pregnant and Breastfeeding Women at Risk of HIV Infection: The Time is Now

In this Perspective, Lynne Mofenson discusses the implications of Mugwanya and colleagues' findings for protection of women against HIV infection during breastfeeding.

Detalles Bibliográficos
Autor principal:	Mofenson, Lynne M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5038968/ https://www.ncbi.nlm.nih.gov/pubmed/27676386 http://dx.doi.org/10.1371/journal.pmed.1002133

Ejemplares similares

Pre-Clinical Evaluation of Tenofovir and Tenofovir Alafenamide for HIV-1 Pre-Exposure Prophylaxis in Foreskin Tissue
por: Else, Laura, et al.
Publicado: (2022)

Urgent appeal to implement pre-exposure prophylaxis for pregnant and breastfeeding women in South Africa
por: Davey, Dvora L Joseph, et al.
Publicado: (2021)

Emerging evidence from a systematic review of safety of pre‐exposure prophylaxis for pregnant and postpartum women: where are we now and where are we heading?
por: Joseph Davey, Dvora L, et al.
Publicado: (2020)

Prophylaxis and Treatment of Pregnant Women for Emerging Infections and Bioterrorism Emergencies
por: Cono, Joanne, et al.
Publicado: (2006)

Topical Tenofovir Pre-exposure Prophylaxis and Mucosal HIV-Specific Fc-Mediated Antibody Activities in Women
por: Fisher, Kimone Leigh, et al.
Publicado: (2020)

Safety of Pediatric HIV Elimination: The Growing Population of HIV- and Antiretroviral-Exposed but Uninfected Infants
por: Mofenson, Lynne M., et al.
Publicado: (2014)

We Must Not Let Protestors Derail Trials of Pre-Exposure Prophylaxis for HIV
por: Lange, Joep M. A
Publicado: (2005)

The effect of tenofovir on renal function in HIV-positive pregnant women
por: Flanagan, Stuart, et al.
Publicado: (2014)

Long-Acting Injectable Drugs for HIV-1 Pre-Exposure Prophylaxis: Considerations for Africa
por: Moyo, Enos, et al.
Publicado: (2022)

Acute Trigeminal Neuralgia Associated with Initiation of Emtricitabine/Tenofovir for HIV Pre-Exposure Prophylaxis
por: Van Slyke, Loraine, et al.
Publicado: (2018)

Tenofovir-Diphosphate as a Marker of HIV Pre-exposure Prophylaxis Use Among East African Men and Women
por: Pyra, Maria, et al.
Publicado: (2019)

Is Long-acting Cabotegravir a Pre-exposure Prophylaxis Option for Women of Childbearing Potential?
por: Sahloff, Eric G, et al.
Publicado: (2022)

Pre-Exposure Prophylaxis for COVID-19 in Pregnant Women
por: Fesler, Melissa C, et al.
Publicado: (2021)

HIV pre-exposure prophylaxis for women
por: Sheth, Anandi N, et al.
Publicado: (2016)

Use of Tenofovir Alafenamide Fumarate for HIV Pre-Exposure Prophylaxis and Incidence of Hypertension and Initiation of Statins
por: Rivera, Adovich S., et al.
Publicado: (2023)

Integration of HIV pre-exposure prophylaxis (PrEP) services for pregnant and breastfeeding women in eight primary care clinics: results of an implementation science study
por: Nelson, Aurelie, et al.
Publicado: (2023)

853. Real-World Persistency of Patients Receiving Tenofovir-Based Pre-Exposure Prophylaxis for the Prevention of HIV Infection in the US
por: Oglesby, Alan, et al.
Publicado: (2021)

Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with men
por: Mizushima, Daisuke, et al.
Publicado: (2023)

The Safety of Tenofovir–Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B
por: Solomon, Marc M., et al.
Publicado: (2016)

1551. Changes in Glomerular Filtration Rate after Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis
por: Rivera, Adovich, et al.
Publicado: (2023)

Impact of postpartum tenofovir-based antiretroviral therapy on bone mineral density in breastfeeding women with HIV enrolled in a randomized clinical trial
por: Stranix-Chibanda, Lynda, et al.
Publicado: (2021)

Frequency of Hepatitis B Virus Resistance Mutations in Women Using Tenofovir Gel as Pre-Exposure Prophylaxis
por: Baxter, Cheryl, et al.
Publicado: (2019)

Offering pre-exposure prophylaxis for HIV prevention to pregnant and postpartum women: a clinical approach
por: Seidman, Dominika L, et al.
Publicado: (2017)

Adherence Predictors in Pregnant Women Living with HIV on Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate
por: Eke, Ahizechukwu C
Publicado: (2022)

Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis
por: Solomon, Marc M., et al.
Publicado: (2014)

Preclinical Considerations for Long-acting Delivery of Tenofovir Alafenamide from Subdermal Implants for HIV Pre-exposure Prophylaxis
por: Gunawardana, Manjula, et al.
Publicado: (2022)

Comparing pharmacologic measures of tenofovir exposure in a U.S. pre-exposure prophylaxis randomized trial
por: Baxi, Sanjiv M., et al.
Publicado: (2018)

Pre-exposure prophylaxis (PrEP) for HIV prevention among people who inject drugs: a global mapping of service delivery
por: Shaw, Graham, et al.
Publicado: (2023)

Pre-exposure prophylaxis for prevention of HIV infection
por: Lee, Joseph Wei En, et al.
Publicado: (2023)

Cost-Effectiveness of Pre-exposure HIV Prophylaxis During Pregnancy and Breastfeeding in Sub-Saharan Africa
por: Price, Joan T., et al.
Publicado: (2016)

“PrEP protects us”: Behavioural, normative, and control beliefs influencing pre-exposure prophylaxis uptake among pregnant and breastfeeding women in Zambia
por: Hamoonga, Twaambo Euphemia, et al.
Publicado: (2023)

Performance and Stability of Tenofovir Alafenamide Formulations within Subcutaneous Biodegradable Implants for HIV Pre-Exposure Prophylaxis (PrEP)
por: Li, Linying, et al.
Publicado: (2020)

Renal impairment associated with tenofovir disoproxil fumarate for antiretroviral therapy and HIV pre-exposure prophylaxis: An observational cohort study
por: Heron, Jack E., et al.
Publicado: (2023)

Clinical trial simulation to evaluate tenofovir disoproxil fumarate/emtricitabine HIV pre-exposure prophylaxis dosing during pregnancy
por: Scott, Rachel K., et al.
Publicado: (2023)

Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01
por: Huang, Yunda, et al.
Publicado: (2023)

Developing evidence-informed indicators to monitor HIV pre-exposure prophylaxis programmes across EU/EEA countries: a multi-stakeholder consensus
por: Vanhamel, Jef, et al.
Publicado: (2023)

HIV Infection-Associated Frailty: The Solution for Now Is Antiretroviral Drugs: A Perspective
por: Klotz, Stephen A., et al.
Publicado: (2019)

Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV
por: Devred, Inès, et al.
Publicado: (2023)

Pre-exposure prophylaxis of HIV
por: Naswa, Smriti, et al.
Publicado: (2011)

Pre-exposure prophylaxis in HIV
por: Khambhati, Ravi, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_hm0aq9tef9plb1np9hl6begqei